Anosmia Clinical Trial
Official title:
Effect of Olfactory Training on Olfactory Dysfunction Patients in Hong Kong Population
- Causes of olfactory dysfunction can be classified into conductive and sensorineural causes. - Conductive causes are mainly due to structural nasal problem, which can be treated by nasal surgery - Sensorineural causes included post-infection, post-head injury, post Head and Neck irradiation and other central nervous system diseases. - Olfactory Training is well established treatment for sensorineural olfactory dysfunction in foreign countries. - Olfactory Training by neurological chemosensory stimulation using aromatic substances delivered via electronic portable aromatic rehabilitation (EPAR) diffuser was proved to be effective treatment in COVID-19 related olfactory dysfunction in recent Hong Kong study. - However, there is a lack of local study on the effect of Olfactory Training in other non-COVID-19 sensorineural causes of olfactory dysfunction in Hong Kong population.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | June 30, 2025 |
Est. primary completion date | June 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Olfactory dysfunction > 6 months and < 5 years Exclusion Criteria: - History of significant head injury (fracture, ICH) - History of brain surgery - History of nasal surgery - Active nasal disease - Active neurological disease - Poor premorbid status/ non-communicable patients - Mentally incompetent patients - <18 years' old - Pregnancy - Hypersensitivity to the aromatic substance. |
Country | Name | City | State |
---|---|---|---|
Hong Kong | Pamela Youde Nethersole Eastern Hospital | Hong Kong |
Lead Sponsor | Collaborator |
---|---|
Pamela Youde Nethersole Eastern Hospital |
Hong Kong,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Olfactory threshold changes after olfactory training after 3 months | Parameter:
Olfactory threshold using Butanol Threshold Test (BTT) |
3 months after starting smell training | |
Primary | Olfactory identification score changes after olfactory training after 3 months | Parameter:
Olfactory identification using Smell Identification Test (UPSIT) |
3 months after starting smell training | |
Primary | Quality of life changes after olfactory training after 3 months | Parameter:
Subjective quality of life score using Sino-Nasal Outcome Test (SNOT-22) |
3 months after starting smell training | |
Primary | Taste and smell changes after olfactory training after 3 months | Parameter:
Subjective smell and taste assessment using Visual Analogue Scale (VAS) |
3 months after starting smell training |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04964414 -
Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT05812209 -
Stellate Ganglion Block to Treat Long COVID 19 Case Series
|
||
Completed |
NCT05445921 -
Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02179554 -
Does Cardiopulmonary Bypass Change Olfaction?
|
||
Completed |
NCT04957563 -
Clinical Utility of Olfactory Rehabilitation: Treatment for Pacients With Neurosensorial Anosmia
|
N/A | |
Terminated |
NCT03680911 -
NAC for Head Trauma-induced Anosmia
|
Phase 3 | |
Completed |
NCT04657809 -
Clinical Assessment of Insulin Fast Dissolving Film in Treatment of Post Infection Anosmia
|
Phase 2 | |
Completed |
NCT04853836 -
Olfactory Disfunction and Co-ultraPEALut
|
Phase 4 | |
Recruiting |
NCT05040659 -
Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2
|
||
Recruiting |
NCT05562050 -
Characteristics of the Anosmic Olfactory Mucosa
|
||
Completed |
NCT05152030 -
The Clinical Applicability of the 'TIB' Olfactory Test Device
|
||
Recruiting |
NCT05384561 -
Olfactory Training as a Treatment for Olfactory Dysfunction Post COVID-19
|
N/A | |
Enrolling by invitation |
NCT04764981 -
Olfactory Training for Olfactory Dysfunction After Coronavirus Disease - 19 (COVID-19)
|
N/A | |
Withdrawn |
NCT04408391 -
Brain MRI Imaging in Patients With SARS-Cov2 (COVID-19) Infection With or Without Anosmia
|
||
Completed |
NCT04361474 -
Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity
|
Phase 3 | |
Completed |
NCT03990766 -
Smell Changes & Efficacy of Nasal Theophylline
|
Phase 2 | |
Completed |
NCT04797936 -
BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19
|
Phase 4 | |
Recruiting |
NCT04528329 -
Anosmia and / or Ageusia and Early Corticosteroid Use
|
Phase 4 | |
Completed |
NCT04789499 -
Smell in Covid-19 and Efficacy of Nasal Theophylline
|
Phase 2 | |
Recruiting |
NCT04384042 -
Malaysian COVID-19 Anosmia Study (Phase 2) - A Nationwide Multicentre Case-Control Study
|